Panvascular diseases,encompassing systemic vascular disorders driven by atherosclerosis,represent the leading cause of global mortality,posing significant challenges in modeling due to their prolonged,multiorgan natur...Panvascular diseases,encompassing systemic vascular disorders driven by atherosclerosis,represent the leading cause of global mortality,posing significant challenges in modeling due to their prolonged,multiorgan nature and complex device-vessel interactions.Current in vitro and in vivo models fall short in recapitulating high-fidelity hemodynamics,long-term monitoring,multi-vascular bed heterogeneity,and three-dimensional(3D)dynamic interactions essential for advancing interventional device development.To address these gaps,we introduce the FLOw framework—a novel panvascular-on-a-chip platform leveraging organ-on-a-chip(OoC)technology.This framework integrates four core modules:Fidelity hemodynamic reconstruction(F)for simulation of physiological/pathological blood flow;Longitudinal physiological surveillance(L)for real-time tracking of chronic processes like endothelialization and inflammation;Omni-vascular bed modeling(O)for simulating coexisting lesions across diverse vascular beds and inter-organ crosstalk;and Whole-space 3D interactive work-flow(W)for evaluating device deployment and biomechanicalinteractions in 3D vascular microenvironments.Guided by the concept of"suitcordance"(defined here as short-term suitability and long-term concordance between devices and vascular tissues),the FLOwplatform enables high-fidelity modeling of panvascular pathologies,such as atherosclerosis-induced downstream diseases(e.g.,myocardial infarction,stroke,diabetic foot)and thrombosis,while facilitating optimization of interventional deviceslike stents,valves,and thrombectomy catheters to achieve post-intervention rebalancing of biomechanical,cellular,and physicochemical-immune ecologies.We review macro-construction foundations,including microfluidic technologies,real-time sensing,cell engineering,and hydrogel-based structural designs,and discuss applications in mechanistic studies and device translation.Future prospects include multi-organ integration,Al-driven analytics,long-term culture,and gene editing for personalized medicine,positioning panvascular-on-a-chip as a paradigm-shifting tool to bridge clinical outcomes,enhancing device-vessel harmony and combating humanity's"number one killer".展开更多
Objective To explore the efficacy of transcatheter closure of patent ductus arteriosus (PDA) with detachable coil and Amplatzer duct occluder (ADO). Methods Transcatheter colsure of PDA was performed in 160 case...Objective To explore the efficacy of transcatheter closure of patent ductus arteriosus (PDA) with detachable coil and Amplatzer duct occluder (ADO). Methods Transcatheter colsure of PDA was performed in 160 cases, aged 4.56±2.67 years, of whom 3 had residual shunt after surgical ligation, 2 had pulmomary stenosis (PS), 1 had coarctation of aorta (COA), 1 had right aortic arch, and 2 had atrial septal defect (ASD). Results Detachable coils (Duct Occlude pfm or Cook Inc) were successfully used in 51 patients with a smallest PDA diameter of 1.86±0.78mm. Amplatzer duct occluders were also successfully performed in other 109 with a moderate to large PDA diameter of 3.89±1.32mm, of whom 3 with PS or COA were performed balloon dilation firstly, and 2 with ASD were performed PDA occlusion firstly; 1 month to 4.8 years follow-up coil or Amplatzer device closure of PDA showed that neither residual shunt nor any complication. Conclusion It is suggested that the detachable coil and Amplatzer duct occluder are simple and safe for the catheter closure from small to large sized PDA.展开更多
Thrombus formation and tissue embedding significantly impair the clinical efficacy and retrievability of temporary interventional medical devices.Herein,we report an insect sclerotization-inspired antifouling armor fo...Thrombus formation and tissue embedding significantly impair the clinical efficacy and retrievability of temporary interventional medical devices.Herein,we report an insect sclerotization-inspired antifouling armor for tailoring temporary interventional devices with durable resistance to protein adsorption and the following protein-mediated complications.By mimicking the phenol-polyamine chemistry assisted by phenol oxidases during sclerotization,we develop a facile one-step method to crosslink bovine serum albumin(BSA)with oxidized hydrocaffeic acid(HCA),resulting in a stable and universal BSA@HCA armor.Furthermore,the surface of the BSA@HCA armor,enriched with carboxyl groups,supports the secondary grafting of polyethylene glycol(PEG),further enhancing both its antifouling performance and durability.The synergy of robustly immobilized BSA and covalently grafted PEG provide potent resistance to the adhesion of proteins,platelets,and vascular cells in vitro.In ex vivo blood circulation experiment,the armored surface reduces thrombus formation by 95%.Moreover,the antifouling armor retained over 60%of its fouling resistance after 28 days of immersion in PBS.Overall,our armor engineering strategy presents a promising solution for enhancing the antifouling properties and clinical performance of temporary interventional medical devices.展开更多
基金supported by the National Natural Science Foundation of China(T2288101 and 82170342)the Shanghai Advanced Materials Key Technology Project Fund of Science and Technology Commission of Shanghai Municipality(25CL2900500)+1 种基金the Medical Engineering Joint Fund of Fudan University(yg2023-01)the AI for Science Foundation of Fudan University(FudanX24AI003).
文摘Panvascular diseases,encompassing systemic vascular disorders driven by atherosclerosis,represent the leading cause of global mortality,posing significant challenges in modeling due to their prolonged,multiorgan nature and complex device-vessel interactions.Current in vitro and in vivo models fall short in recapitulating high-fidelity hemodynamics,long-term monitoring,multi-vascular bed heterogeneity,and three-dimensional(3D)dynamic interactions essential for advancing interventional device development.To address these gaps,we introduce the FLOw framework—a novel panvascular-on-a-chip platform leveraging organ-on-a-chip(OoC)technology.This framework integrates four core modules:Fidelity hemodynamic reconstruction(F)for simulation of physiological/pathological blood flow;Longitudinal physiological surveillance(L)for real-time tracking of chronic processes like endothelialization and inflammation;Omni-vascular bed modeling(O)for simulating coexisting lesions across diverse vascular beds and inter-organ crosstalk;and Whole-space 3D interactive work-flow(W)for evaluating device deployment and biomechanicalinteractions in 3D vascular microenvironments.Guided by the concept of"suitcordance"(defined here as short-term suitability and long-term concordance between devices and vascular tissues),the FLOwplatform enables high-fidelity modeling of panvascular pathologies,such as atherosclerosis-induced downstream diseases(e.g.,myocardial infarction,stroke,diabetic foot)and thrombosis,while facilitating optimization of interventional deviceslike stents,valves,and thrombectomy catheters to achieve post-intervention rebalancing of biomechanical,cellular,and physicochemical-immune ecologies.We review macro-construction foundations,including microfluidic technologies,real-time sensing,cell engineering,and hydrogel-based structural designs,and discuss applications in mechanistic studies and device translation.Future prospects include multi-organ integration,Al-driven analytics,long-term culture,and gene editing for personalized medicine,positioning panvascular-on-a-chip as a paradigm-shifting tool to bridge clinical outcomes,enhancing device-vessel harmony and combating humanity's"number one killer".
文摘Objective To explore the efficacy of transcatheter closure of patent ductus arteriosus (PDA) with detachable coil and Amplatzer duct occluder (ADO). Methods Transcatheter colsure of PDA was performed in 160 cases, aged 4.56±2.67 years, of whom 3 had residual shunt after surgical ligation, 2 had pulmomary stenosis (PS), 1 had coarctation of aorta (COA), 1 had right aortic arch, and 2 had atrial septal defect (ASD). Results Detachable coils (Duct Occlude pfm or Cook Inc) were successfully used in 51 patients with a smallest PDA diameter of 1.86±0.78mm. Amplatzer duct occluders were also successfully performed in other 109 with a moderate to large PDA diameter of 3.89±1.32mm, of whom 3 with PS or COA were performed balloon dilation firstly, and 2 with ASD were performed PDA occlusion firstly; 1 month to 4.8 years follow-up coil or Amplatzer device closure of PDA showed that neither residual shunt nor any complication. Conclusion It is suggested that the detachable coil and Amplatzer duct occluder are simple and safe for the catheter closure from small to large sized PDA.
基金supported by the National Natural Science Foundation of China,China(Project 82202325,82072072,32171326,32261160372)the Guangdong Basic and Applied Basic Research Foundation,China(2022B1515130010,2021A1515111035)+2 种基金Dongguan Science and Technology of Social Development Program,China(20231800906311,20231800900332)China Postdoctoral Science Foundation,China(2022M721524)Leading Talent Project of Guangzhou Development District,China(2020-L013)。
文摘Thrombus formation and tissue embedding significantly impair the clinical efficacy and retrievability of temporary interventional medical devices.Herein,we report an insect sclerotization-inspired antifouling armor for tailoring temporary interventional devices with durable resistance to protein adsorption and the following protein-mediated complications.By mimicking the phenol-polyamine chemistry assisted by phenol oxidases during sclerotization,we develop a facile one-step method to crosslink bovine serum albumin(BSA)with oxidized hydrocaffeic acid(HCA),resulting in a stable and universal BSA@HCA armor.Furthermore,the surface of the BSA@HCA armor,enriched with carboxyl groups,supports the secondary grafting of polyethylene glycol(PEG),further enhancing both its antifouling performance and durability.The synergy of robustly immobilized BSA and covalently grafted PEG provide potent resistance to the adhesion of proteins,platelets,and vascular cells in vitro.In ex vivo blood circulation experiment,the armored surface reduces thrombus formation by 95%.Moreover,the antifouling armor retained over 60%of its fouling resistance after 28 days of immersion in PBS.Overall,our armor engineering strategy presents a promising solution for enhancing the antifouling properties and clinical performance of temporary interventional medical devices.
